AlphaCentric Advisors LLC Purchases 71,500 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

AlphaCentric Advisors LLC grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 55.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 201,500 shares of the biopharmaceutical company’s stock after purchasing an additional 71,500 shares during the quarter. Dynavax Technologies makes up approximately 1.7% of AlphaCentric Advisors LLC’s investment portfolio, making the stock its 13th largest position. AlphaCentric Advisors LLC owned approximately 0.15% of Dynavax Technologies worth $2,245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Dynavax Technologies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after purchasing an additional 126,458 shares during the period. Kynam Capital Management LP boosted its stake in shares of Dynavax Technologies by 180.0% during the first quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after purchasing an additional 2,725,397 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after purchasing an additional 53,600 shares during the period. Great Point Partners LLC boosted its stake in shares of Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Dynavax Technologies during the second quarter valued at $17,615,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research note on Tuesday, October 15th. The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th.

Dynavax Technologies Stock Up 0.1 %

NASDAQ:DVAX opened at $11.79 on Tuesday. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The company has a 50-day moving average of $11.07 and a 200 day moving average of $11.22. The firm has a market cap of $1.54 billion, a PE ratio of 107.19 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same period in the prior year, the firm posted $0.03 earnings per share. As a group, research analysts anticipate that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.